Compliance Rate
Compliance Rate
0%
Compliant submissions
0
Incompliant submissions
0
Total trials
0
My Organizations' Clinical Trials
Showing 4 of 4 entries
View as:
Phase: N/A
Priority: Normal
Start: 05/01/19
End: 05/01/21
Due: 05/01/22
Phase: N/A
Priority: Normal
Start: 06/23/24
End: 03/31/27
Due: 03/31/28
Phase: N/A
Priority: Normal
Start: 08/16/24
End: 12/31/26
Due: 12/31/27
Phase: N/A
Priority: Normal
Start: 08/15/24
End: 07/31/27
Due: 07/31/28
| Title | NCT ID | Organization | User | Status | Start Date | End Date | Reporting Due Date | Last Checked | User Role | Org Created |
|---|---|---|---|---|---|---|---|---|---|---|
| Toripalimab Combined With S1 and Albumin Paclitaxel in Patients With Advanced Biliary Tract Cancer | NCT04027764 | Dai, Guanghai | user2@example.com | None | 2019-05-01 | 2021-05-01 | 2022-05-01 | - | - | 2025-07-14 |
| Liposomal Irinotecan + Oxaliplatin + Bevacizumab Versus Liposomal Irinotecan + 5-FU/LV | NCT06782685 | Dai, Guanghai | user2@example.com | None | 2024-06-23 | 2027-03-31 | 2028-03-31 | - | - | 2025-07-14 |
| Safety and Efficacy of Fruquintinib Plus Chidamide and Sintilimab in the Third and Later Line Treatment of MSS/pMMR Metastatic Colorectal Cancer | NCT06685276 | Dai, Guanghai | user2@example.com | None | 2024-08-16 | 2026-12-31 | 2027-12-31 | - | - | 2025-07-14 |
| Phase Ⅱ Clinical Study of Surufatinib Combined With Gemcitabine and Cisplatin Plus Durvalumab/Pembrolizumab Regimen in the Treatment of Advanced Biliary Tract Cancer | NCT06708858 | Dai, Guanghai | user2@example.com | None | 2024-08-15 | 2027-07-31 | 2028-07-31 | - | - | 2025-07-14 |